Navigation Links
Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Date:2/7/2008

uisitions, and, in general, anticipated financial results for 2008. Actual performance and benefits results may differ materially from those set forth in this press release due to risks and uncertainties inherent in Digirad's business including, without limitation, changes in business conditions, technology, customers' business conditions, work force, suppliers, business prospects, economic outlook, operational policy or structure, acceptance and use of Digirad's camera systems and services, reliability, recalls, and other risks detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward looking statements, which speak only as of the date hereof. All forward looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward looking statements contained herein.

Digirad Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

(unaudited) (unaudited)

Revenues:

DIS $13,420 $11,606 $52,440 $49,614

Product 5,403 5,641 21,507 22,312

Total revenues 18,823 17,247 73,947 71,926

Cost of revenues:

DIS 10,749 8,595 39,520 37,675

Product 3,582 3,742 13,909 15,192

Total cost of revenues 14,331
'/>"/>

SOURCE Digirad Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
2. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
3. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
4. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
5. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference Call
7. Baxa Corporation Launches New Web Site
8. CuraGen Corporation Receives Notification from NASDAQ
9. Healionics Corporation Completes Series A Financing
10. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008
11. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MINNEAPOLIS , Jan. 15, 2014 ­ RedBrick ... and behavior change technology, today announces that EmblemHealth ... insurer and wellness company, is now providing the RedBrick ... digital coaching program, to all of its members. EmblemHealth ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing ... two definitive license agreements with University Health Network (UHN) and ... , granting Trillium exclusive worldwide rights to commercialize two immunology ... cancer. , ...
... of animals and plants is the most important technological ... species has occurred as humans have used individuals carrying ... issue of Nature an international team led ... the secrets underlying the remarkable development of the domestic ...
... ... ... , ... , , , , ...
Cached Biology Technology:Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 2Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 3Scientific breakthrough in genetic studies of animal domestication 2Toxikon Corporation Hosts Extractables and Leachables Spring Seminar 2Toxikon Corporation Hosts Extractables and Leachables Spring Seminar 3
(Date:7/10/2014)... yellow crazy ant Anoplolepis gracilipes is ranked amongst ... for catastrophic ecological impacts on islands. A new study published ... examines and assesses the effects and dangers of the introduction ... the mature palm forest of the Valle de Mai, a ... forest of Valle de Mai is a unique ecosystem containing ...
(Date:7/10/2014)... the West African nation Burkina Faso today have ... Press has the potential to increase access to ... and in communities by combining a lower-dose formulation ... acetate)with the BD Uniject injection system. , Burkina ... expected to begin introducing Sayana Press in 2014, ...
(Date:7/9/2014)... pivotal in the development of cancer, viral infection and ... question about one of the most widely-researched proteins in ... of thousands of research papers and millions of pounds ... in Professor Sir Philip Cohen,s laboratory at the University ... is activated. The results are published today ...
Breaking Biology News(10 mins):Invasion of yellow crazy ant in a Seychelles UNESCO palm forest: Threats and solutions 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3Research reveals how key controller protein is switched on 2
... Santa Barbara, Calif. UC Santa Barbara resource economists ... effects of a fisheries management system implemented by the National ... is funded as part of a $1 million West Coast ... and its partners. The "catch shares" program was created ...
... Md. -- Each year the American Society of Plant ... investigators through a competitive process to attend the Plant ... Young Investigator Travel Award (WYITA) program is to increase ... as an independent scientist in academia, industry, or government ...
... Childrens Research Institute and the University of Melbourne have ... allergy. It is hoped the test would be ... minimise over-diagnosis of peanut allergy in the community. ... standard for diagnosing peanut allergy, and while an oral ...
Cached Biology News:UCSB researchers to examine the effects of year-old NOAA West Coast 'Catch Shares' program 2American Society of Plant Biologists honors early career women scientists 2Test to improve peanut allergy diagnosis 2
...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
Biology Products: